All In Biotech

Drug Trial Radar · NCT04075526

Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty

Last checked: Nov 19, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 2,129 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,129

Actual

Start

Oct 1, 2019

Primary completion

Jan 1, 2024

Study completion Dec 13, 2025

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, controlled, open label, parallel four-arm design, multi-center study to compare different intraoperative interventions in the prevention of acute PJI development.

Conditions

  • Osteoarthritis

Interventions

  • Povidone iodineDrug

    To create the dilute solution, a staff member will draw up 17.5 mL of 10% povidone iodine with a syringe and mix it with 500 mL of normal saline, resulting in a dilution of 0.35% povidone iodine solution for use before wound closure.

  • Vancomycin powderDrug

    2 grams of vancomycin powder will be applied to the wound and will be distributed so that approximately 1 gram is administered deep to the fascia and 1 gram superficial to the fascia

  • ConventionalOther

    No additional steps in management are required for the control arm of the study besides lavage with 1 L of isotonic sodium chloride solution without antibiotics. No vancomycin powder or dilute povidone iodine lavage would be utilized in this cohort

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Periprosthetic Infection (PJI) After Elective Total Joint Arthroplasty.Time frame: 90 Days

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Eisenhower Health

    Rancho Mirage, California

  • Centura Health

    Denver, Colorado

  • Cleveland Clinic Florida

    Weston, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Boston Medical Center

    Boston, Massachusetts

  • New England Baptist Hospital

    Boston, Massachusetts

  • The Orthopedic Institute of New Jersey

    Sparta, New Jersey

  • New York University Dept of Orthopedic Surgery

    New York, New York

  • Hospital for Special Surgery

    New York, New York

  • Mount Sinai Hospital

    New York, New York

  • Columbia

    New York, New York

  • St. Francis Hospital

    Roslyn, New York

  • Cleveland Clinic Ohio

    Cleveland, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.